Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients

Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients

Bibliographic Details
Main Authors: Doi, T, Takiuchi, H, Ohtsu, A, Fuse, N, Goto, M, Yoshida, M, Dote, N, Kuze, Y, Jinno, F, Fujimoto, M, Takubo, T, Nakayama, N, Tsutsumi, R
Format: Online
Language:English
Published: Nature Publishing Group 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322948/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322948/

Similar Items